Register Login

XENCOR INC (XNCR)

(10% Negative) XENCOR INC (XNCR) Announces Delay in contained Trials for future operations Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot May 5, 2026, 1:04 p.m.

    📋 XENCOR INC (XNCR) - Clinical Trial Update

    Filing Date: 2026-05-05

    Accepted: 2026-05-05 08:41:27

    Event Type: Clinical Trial Update

    Event Details:

    XENCOR INC (XNCR) Announces Clinical Trial Update XENCOR INC (XNCR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: contained, management
    • Diseases/Conditions: future operations
    • Clinical Stage: Phase 1 Study, clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Global Phase 2b Study
      • targeting TL1A across autoimmune and inflammatory diseases Anti-TL1A class could capture ~1/3 of total market for advanced therapy in IBD1 TL1A Expected to be Cornerstone of Advanced Therapy in IBD & TAM Expanding to AID Broadly Multi-indication immune franchise opportunities with several ongoing proof-of-concept studies representing ~$88b in global TAM by 2030
      • targeting TNF and IL23p19 in Crohn’s disease1 Full length bispecific antibody Xtend + FcKO XmAb412 robustly suppresses both TL1A and IL23 inflammatory pathways2 1 Sands BE, et al. Abstract 979f. Presented at: Digestive Disease Week (DDW) 2026
      • targeting TL1A in large and growing market for biologic therapies to treat IBD Program Target 2025

    🔬 Clinical Development Pipeline (XENCOR INC):

    Product Type Development Stage Therapeutic Area Source
    XmAb819 Other Phase PHASE1 Clear Cell Renal Cell Carcinoma ClinicalTrials.gov
    XmAb942 Other Phase PHASE1 Ulcerative Colitis (UC) ClinicalTrials.gov
    vudalimab monotherapy Drug Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer ClinicalTrials.gov
    Placebo Other Phase PHASE1 Allergic Rhinitis ClinicalTrials.gov
    vudalimab + cabazitaxel or docetaxel Other Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer ClinicalTrials.gov
    vudalimab + docetaxel Other Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer ClinicalTrials.gov
    vudalimab + olaparib Other Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer ClinicalTrials.gov
    vudalimab + carboplatin + cabazitaxel Other Phase PHASE2 Metastatic Castration-Resistant Prostate Cancer ClinicalTrials.gov
    XmAb5574 Other Phase PHASE1 Chronic Lymphocytic Leukemia ClinicalTrials.gov
    XmAb7195 Other Phase PHASE1 Allergic Rhinitis ClinicalTrials.gov
    XmAb5871 Other Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Placebo to match XmAb5871 Other Phase PHASE2 Systemic Lupus Erythematosus ClinicalTrials.gov
    XmAb14045 Other Phase PHASE1 Acute Myelogenous Leukemia ClinicalTrials.gov
    XmAb18087 Other Phase PHASE1 Neuroendocrine Tumor ClinicalTrials.gov
    XmAb20717 Other Phase PHASE1 Melanoma ClinicalTrials.gov
    XmAb27564 Other Phase PHASE1 Safety in Healthy Volunteers ClinicalTrials.gov
    AMG 424 Other Phase PHASE1 Relapsed/ Refractory Multiple Myeloma ClinicalTrials.gov
    Pembrolizumab (Keytruda®) Other Phase PHASE1 Melanoma ClinicalTrials.gov
    XmAb®22841 Other Phase PHASE1 Melanoma ClinicalTrials.gov
    XmAb18087 ± Pembrolizumab Other Phase PHASE1 Merkel Cell Carcinoma ClinicalTrials.gov
    Regorafenib Other Phase PHASE2 Colorectal Cancer ClinicalTrials.gov
    Lenalidomide Other Phase PHASE2 Diffuse Large-cell B-cell Lymphoma ClinicalTrials.gov
    Tafasitamab Other Phase PHASE2 Diffuse Large-cell B-cell Lymphoma ClinicalTrials.gov
    Plamotamab Other Phase PHASE2 Diffuse Large-cell B-cell Lymphoma ClinicalTrials.gov
    Yervoy® (ipilimumab) Other Phase PHASE1 Melanoma (Excluding Uveal Melanoma) ClinicalTrials.gov
    XmAb®23104 Other Phase PHASE1 Melanoma (Excluding Uveal Melanoma) ClinicalTrials.gov
    Keytruda® (pembrolizumab) Other Phase PHASE1 Solid Tumors ClinicalTrials.gov
    XmAb662 Other Phase PHASE1 Solid Tumors ClinicalTrials.gov
    XmAb13676 Other Phase PHASE1 B-cell Non-Hodgkins Lymphoma ClinicalTrials.gov
    vudalimab Other Phase PHASE2 Ovarian Cancer ClinicalTrials.gov
    XmAb23104 Other Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    XmAb22841 Other Phase PHASE1 Metastatic Melanoma ClinicalTrials.gov
    XmAb®808 Other Phase PHASE1 Head and Neck Squamous Cell Carcinoma ClinicalTrials.gov
    PSMA PET Scan Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Magnetic Resonance Imaging Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    FDG-Positron Emission Tomography Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Enzalutamide Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Docetaxel Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Computed Tomography Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Bone Scan Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Biospecimen Collection Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Abiraterone Other Phase PHASE1 Castration-Sensitive Prostate Carcinoma ClinicalTrials.gov
    Pembrolizumab + Carboplatin + Pemetrexed Other Phase PHASE1 Nonsquamous Non-small Cell Lung Cancer ClinicalTrials.gov
    Vudalimab + Carboplatin + Pemetrexed Other Phase PHASE1 Nonsquamous Non-small Cell Lung Cancer ClinicalTrials.gov
    XmAb541 Other Phase PHASE1 Ovarian Cancer ClinicalTrials.gov
    XmAb2513 BIOLOGICAL Phase PHASE1 Hodgkin Lymphoma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: XENCOR INC
    • Ticker Symbol: XNCR

Search

News categories